• Chen N, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 2019; doi: 10.1056/NEJMoa1813599;

  • Chen N, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 2019; doi: 10.1056/NEJMoa1901713.

Roxadustat for Anemia: New Trials in Dialysis and Nondialysis Patients

Restricted access

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is an effective treatment for anemia both in nondialysis patients with chronic kidney disease (CKD) and in long-term dialysis patients, according to a pair of industry-sponsored trials recently published in the New England Journal of Medicine (NEJM).

Nondialysis trial

The nondialysis CKD trial included 154 patients who were enrolled at 29 sites in China. All the patients with CKD had baseline hemoglobin levels of 7.0 to less than 10 g/dL. None of the patients had received erythropoiesis-stimulating agents for at least the previous 5 weeks.

The researchers note that in China,